Founded in 2007 by Rudolf Jaenisch with backing from Arch Venture Partners, Fate Therapeutics’ corporate headquarters are in San Diego, California. It also has a subsidiary in Ottawa, Canada. Fate Therapeutics is an innovative biotechnology company developing novel stem cell modulators and biologic or small molecule compounds that guide cell fate. [Read more…]
Do You Know the Top Quality Guarantees Among U.S. Cord Blood Banks?
Cord Blood Registry (CBR) is the largest U.S. cord blood bank. To date, CBR has stored more than 500,000 cord blood and cord tissue samples, while ViaCord has stored 350,000 samples and Cryo-Cell has stored 240,000 samples.
While these storage counts may include cord blood and tissue units collected by their international divisions, these three industry players are the clear market leaders within the U.S. private cord blood banking industry. [Read more…]
Biostage Announces the Use of Its Esophageal Implant Product Candidate in a Patient
Procedure was approved via the FDA’s single-use expanded access program and was performed at a major U.S. hospital.
HOLLISTON, Mass., Aug. 7, 2017 /PRNewswire/ — Biostage Inc., (Nasdaq: BSTG), (“Biostage” or the “Company”), a biotechnology company developing bioengineered organ implants to treat cancer, congenital abnormalities and other life-threatening conditions of the esophagus, bronchus and trachea, today announced the use of Biostage’s Cellspan Esophageal Implant product candidate in a patient at a major U.S. hospital via an FDA-approved single-use expanded access application.
Donor Egg Bank to Provide Free Cord Blood Processing through FamilyCord
World’s Largest Frozen Egg Bank offers a Lifetime of Security
Rockville, MD, Aug. 1, 2017— Donor Egg Bank, a California Cryobank company, continues to set the standard for the frozen donor egg industry by offering a truly once in lifetime opportunity to their intended parents – free processing for their future babies’ cord blood stem cells through sister company FamilyCord – a $1,500 savings.
AgeX Therapeutics Obtains $10 Million in Capital and Commences Operations
August 02, 2017, ALAMEDA, Calif.–AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE MKT: BTX), today reported that it has successfully raised $10 million in equity financing to fund its operations. Following the financing, BioTime continues to own about 87% of AgeX’s outstanding shares. The financing is expected to fund preclinical development at AgeX as well as building the company’s operational infrastructure. The financing may also lead to a registration and distribution of a to-be-determined percentag of the AgeX shares to BioTime shareholders, after which AgeX would trade as a public company. [Read more…]
- « Previous Page
- 1
- …
- 215
- 216
- 217
- 218
- 219
- …
- 314
- Next Page »